Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

Adaptogens Market is Segmented by Type (Organic, Synthetic), by Application (Food and Beverages, Nutraceuticals, ...

Indivior PLC’s recovery hinges on Sublocade’s momentum and market trends, though risks persist in litigation and earnings.

Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Inductio ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Transplanting bacteria from the feces of healthy people into the guts of mice and patients with fibromyalgia successfully ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK ® (beremagene geperpavec-svdt) for ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

Whether you're getting started with PCR, sequencing, or diagnostics, tubes of custom DNA oligos will give you the exact, ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...